Abstract��OBJECTIVE To investigate the related factors effecting the teicoplanin concentration..METHODS The patients�� information who accepted teicoplanin therapy and their plasma on the fourth day treatment were collected. The plasma was processed and detected by HPLC method. A multiple linear regression method was used to explore the relationship between the teicoplanin concentration and other factors. RESULTS The result of multiple linear regression shows that the teicoplanin concentration relates with the creatine clearance and hypersensitive C-reactive protein. CONCLUSION The teicoplanin treatment regimen could be altered by the level of patients�� creatine clearance and hypersensitive C-reactive protein in order to deliver a better individual treatment.
���ٸ�, ����ϼ, ��߮. �濼������ѪҩŨ�ȼ�⼰Ӱ�����ط���[J]. �й�ҩѧ��־, 2019, 54(8): 654-658.
ZHANGRong-ge, ZHANGRui-xia, ZHANGYi. Determination of Teicoplanin in Human Plasma and Related Factors Analysis. Chinese Pharmaceutical Journal, 2019, 54(8): 654-658.
JI C. Antibacterial activity and clinical application of teicoplanin [J]. World Notes Antibiot(����ҽҩ:�����طֲ�), 2001,22(3):27-29.
[2]
CHEN Y, WANG S Y, HU G Y. Determination of teicoplanin in injection by bioassay[J]. Chin Pharm J(�й�ҩѧ��־), 2002,37(4):64-66.
[3]
WILSON A, PETER R. Clinical pharmacokinetics of teicoplanin[J]. Clin Pharmacokinetics, 2000, 39(3):167-183.
[4]
ROBERTS J A, STOVE V, WAELE J J, et al. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI study[J]. Inter J Antimicrob Agents, 2014, 43(5):423-430.
[5]
DENG J J, WEI W. Advances in analytical methods of teicoplanin, a glycopeptide antibiotic[J]. J Mil Surge Southwest China(���Ͼ�ҽ), 2009,11(5):925-926.
[6]
MATSUMOTO K, KANAZA W, WATANABE E, et al. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections[J]. Bio Pharm Bull, 2013, 36(6):1024-1026.
[7]
ZU Y N, ZHANG H, ZHOU L J, et al. Monitoring of drug concentrations of elderly patients with severe Gram-positive bacteria infections treated with different dosages of teicoplanin and assessment of curative effect[J].Chin J Nosocom(�л�ҽԺ��Ⱦѧ��־), 2016, 26(23):109-111.
[8]
SHI X L, ZHOU L J. Analysis of 51 cases of teicoplanin administration under the guidance of blood drug concentration monitoring[J]. Chin Pharm Aff(�й�ҩ��), 2016, 30(8):96-99.
[9]
YAMADA T, KUBOTA T, NAKAMURA M, et al. Evaluation of teicoplanin concentrations and safety analysis in neonates[J]. Inter J Antimicrobial Agents, 2014, 44(5):458-462.
[10]
China National Prescription Collection and Editorial Committee. Chinese National Formulary Chemicals and Biological Products(����ҩ���ٴ�Ӧ��ָ��ԭ��)[M]. Beijing: People��s Military Medical Publishing House, 2010: 475.
[11]
JIA H J, ZHENG X H, ZHAO Z Y. The interpretation of guidelines for clinical application of antibiotics(2015)[J]. Tianjin Pharm(���ҩѧ),2016,28(5):46-48.
[12]
SUN Z. Medical statistics[J]. Med Statist(ҽѧͳ��ѧ), 2002,24(29):253-257.
[13]
BEGG E J, LBARCLA Y M, KIRKPATRICK C M. The therapeutic monitoring of antimicrobial agents[J]. Br J Clin Pharmacol, 2001, 52(suppl 1):35-43.
[14]
FANOS V, KACET N, MOSCONI G. A review of teicoplanin in the treatment of serious neonatal infections[J]. Springer Verlag, 1997, 156(6):423-427.
[15]
TAKASHI N, YOSHINORII M, TOMOFUMI O, et al. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics[J]. Inter J Antimicrob Agents, 2010, 35(5):507-510.
[16]
HU S S, DONG Y L. Pharmacokinetics and administration regimen of teicoplanin in different populations[J]. Northwest Pharm J(����ҩѧ��־), 2009,24(3):232-234.
[17]
ROWLAND M. Clinical pharmacokinetics of teicoplanin[J]. Clin Pharmacol, 1990, 18(3):184-209.
[18]
SMITHERS-J A, THOMPSON-G A, KENNY-M T, et al. Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30 mg��kg-1[J]. Biopharm Drug Dispos, 1992, 13(8):571-581.
[19]
UHART M, LEROY B, MICHAUD A, et al. Variabilit�� pharmacocin�� tique inter-et intra-individuellelors de traitements par teicoplanine chez les sujets ag��s[J]. Med Mal Infect, 2013, 43(7):295-298.
[20]
FEDERICO P, PIERLUIGI V, ANNA C, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages[J]. Clin Pharmacol, 2004, 43(6):405-415.
[21]
ZHANG X H, LI G T, ZHANG Z L. Clinical significances of C-reactive protein and hypersensitive C-reactive protein[J]. Chin J Allerg Clin Immunol(�л��ٴ����ߺͱ�̬��Ӧ��־), 2011,5(1):74-79.
[22]
SIERRA R, RELLO J, BAILÉN M, et al. C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome[J]. Springer Verlag, 2004, 30(11):2038-2045.
2019, Vol. 54 
